#South Korea #Seoul #PCR Technology #Seegene #CURECA

Seegene Unveils CURECA™: Revolutionizing PCR Testing

In a remarkable presentation at ESCMID Global 2025, Seegene Inc., a trailblazer in molecular diagnostics, introduced CURECA™, an upcoming automated PCR solution set to redefine laboratory workflows, offering customizable pre-treatment features. The innovative system aims to streamline the entire PCR process, covering everything from sample pre-processing to results analysis.

Transforming Laboratory Automation

CURECA™ stands for Continuous Unlimited Random Access Customizable Automation and is designed to provide complete automation across the PCR testing workflow. Seegene's mission is not only to improve operational efficiency in labs but to lay down a new global standard in molecular diagnostics.

The core functionality of CURECA™ revolves around two key components: the Customizable Pre-treatment System (CPS) and the Comprehensive Expandable Full Automation (CEFA). The CPS handles sample loading and pre-treatment processing, while CEFA manages the precise steps involved in nucleic acid extraction, PCR setup, genetic amplification, and result analysis.

Enhancing Sample Handling

The pre-treatment stage in molecular diagnostics is often complex, involving careful manipulation of specimens such as feces, urine, blood, and sputum. Traditionally reliant on manual labor by trained professionals, Seegene's CPS is engineered to automate critical steps such as sample sorting, centrifugation, vortexing, and thermal treatment. Importantly, CPS can operate independently or be integrated into other laboratory testing areas, including hematology and biochemistry, which will greatly enhance its applicability to clinical lab workflows.

Flexible and Modular Design

The modular design of CURECA™ offers laboratories flexibility in configuring the system to fit their operational needs. By supporting automation throughout the workflow, this system endeavors to mitigate the risks associated with human error, allowing for high-throughput PCR testing around the clock, every day of the week.

CURECA™ Concept Introduction

The conceptual video presented during the ESCMID Global 2025 highlighted the system's workflow from sample loading to result analysis, showcasing its adaptability across different laboratory environments. Seegene aims to establish an infrastructure that promotes continuous PCR testing with minimal oversight.

Aiming for a Disease-Free World

Dr. Jong-Yoon Chun, Seegene's founder and CEO, articulated a vision for CURECA™ that encompasses a commitment to enhancing healthcare accessibility and outcomes. "Until now, there has not been a solution capable of fully automating pre-treatment of PCR specimens. We aim to set a new global benchmark and reshape the future of molecular diagnostics,” he stated.

The initiative aligns with Seegene's broader goal to share advanced technologies, making sophisticated molecular diagnostics more accessible worldwide. CURECA™ marks an initial stride towards Dr. Chun's vision of fostering a disease-free world.

Addressing Current Educational Needs

The offerings at ESCMID 2025 were under the theme of "Redefining MDx," where Seegene presented its current portfolio of real-time syndromic PCR assays. Sessions were held to discuss the evolving role of molecular diagnostics in tackling antibiotic resistance and the diagnostic needs in the post-COVID-19 era.

Among the key assays showcased were the Entero DR and STI-AMR, designed for timely and informed treatment decisions in infectious disease management. Seegene’s extensive experience in research and development reflects a robust commitment to advancing medical diagnostics.

As a pioneer in the field, Seegene has provided over 340 million COVID-19 tests globally, demonstrating the reliability and effectiveness of its real-time syndromic PCR technology which can analyze multiple pathogens simultaneously.

This technological leap with CURECA™ solidifies Seegene's position at the forefront of molecular diagnostics as they work collaboratively across global platforms to realize a future without infectious diseases.

For further details on Seegene’s groundbreaking work and CURECA™, visit Seegene’s official website.